ArticleCancers2019
Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice.
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Advancing Systemic Treatment beyond First Line for Advanced Hepatocellular Carcinoma.Current oncology reports · 2026Review
- Randomized phase II study comparing two doses of regorafenib in second-line treatment for advanced hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2025Article
- Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment.ESMO gastrointestinal oncology · 2025Article
- Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives.Discover oncology · 2024Review
- Efficacy and outcome of molecular targeted therapies in elderly patients with hepatocellular carcinoma: Relative dose intensity associated with overall survival.Cancer medicine · 2023Observational
- Article
- Gelatin sponge microparticles for transarterial chemoembolization combined with regorafenib in hepatocellular carcinoma: a single-center retrospective study.Journal of gastrointestinal oncology · 2022Article
- Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment.Journal of personalized medicine · 2022Article
- Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements.Liver cancer · 2022Review
- Article
- Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.Liver cancer · 2021Article
- Article
- Impact of Multi-Drug Sequential Therapy on Survival in Patients with Unresectable Hepatocellular Carcinoma.Liver cancer · 2021Article
- Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib.Internal medicine (Tokyo, Japan) · 2021Article
- Experience with regorafenib in the treatment of hepatocellular carcinoma.Therapeutic advances in gastroenterology · 2021Review
- Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC.Journal of hepatocellular carcinoma · 2021Review
- Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.Liver cancer · 2020Review
- Promising diagnostic and prognostic value of six genes in human hepatocellular carcinoma.American journal of translational research · 2020Article
- Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib.Therapeutic advances in medical oncology · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to explore the relative dose intensity (RDI) and post-regorafenib treatments in regorafenib therapy.
methodsThe medical records of 38 patients treated with regorafenib between July 2017 and June 2019 at our institution were collected. The RDI of regorafenib for the first month (1M-RDI) was calculated.
resultsThe overall survival (OS) and progression-free survival (PFS) were 12.4 and 3.7 months. The objective response rate and disease control rate were 13.2% and 71.1%. The median total dose of regorafenib in the first month was 2080 mg (240-3360 mg), and the median 1M-RDI was 61.9% (7.1%-100%). Patients with 1M-RDI ≥ 50% showed significantly longer OS and PFS than patients with 1M-RDI < 50% (HR 0.19, 95% CI 0.08-0.48, p = 0.0004 and HR 0.2, 95% CI 0.08-0.52, p = 0.0008). A 1M-RDI ≥ 50% (HR 0.18, 95% CI 0.06-0.55, p = 0.002) and hand-foot skin reaction (HR 0.03, 95% CI 0.008-0.16, p < 0.0001) were independently associated with OS. Post-regorafenib therapies were performed in 19 (86.4%) of 22 patients who had stopped regorafenib due to disease progression.
conclusionA 1M-RDI ≥ 50% is clinically significant. Post-regorafenib therapies are commonly performed in real-world practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.